Novacyt (LON:NCYT – Get Free Report) released its quarterly earnings data on Wednesday. The company reported GBX (8) EPS for the quarter, Digital Look Earnings reports. Novacyt had a negative net margin of 103.08% and a negative return on equity of 96.44%.
Novacyt Stock Down 4.8%
Shares of Novacyt stock traded down GBX 2 during trading on Thursday, hitting GBX 40. 62,794 shares of the stock traded hands, compared to its average volume of 174,469. The stock’s fifty day simple moving average is GBX 41.85 and its 200 day simple moving average is GBX 39.13. Novacyt has a 52-week low of GBX 26.60 and a 52-week high of GBX 86. The firm has a market cap of £29.00 million, a P/E ratio of -1.25 and a beta of 1.11. The company has a current ratio of 4.74, a quick ratio of 4.46 and a debt-to-equity ratio of 44.74.
About Novacyt
The Company is divided into three business segments:
Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel
Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments
Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)
Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.
Recommended Stories
- Five stocks we like better than Novacyt
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
- First Watch’s Growth Story Meets a Reality Check
- Down 50% and Climbing Again: 3 AI Stocks Rebuilding After Brutal Pullbacks
- Micron’s Earnings Reveal Why the AI Memory Boom May Last Longer
Receive News & Ratings for Novacyt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novacyt and related companies with MarketBeat.com's FREE daily email newsletter.
